Glidimin PM 2 Tablet SR is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 2 mg, Metformin 500 mg, and Pioglitazone 15 mg, providing a multifaceted approach to glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby enhancing endogenous insulin levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved glucose utilization and lipid metabolism. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and reducing gastrointestinal side effects commonly associated with Metformin. Glidimin PM 2 is indicated for patients inadequately controlled on monotherapy or dual therapy, offering improved glycemic control through complementary mechanisms. It should be used alongside diet and exercise for optimal efficacy. Caution is advised in patients with hepatic, renal, or cardiac impairment, and regular monitoring of blood glucose, liver function, and hematologic parameters is recommended. This combination therapy facilitates comprehensive management of hyperglycemia, aiming to reduce the risk of diabetes-related complications.